MétaCan
Menu
← Back to cohort
Record W4248454000 · doi:10.1093/pch/21.5.260

Letters to the Editor

2016· article· en· W4248454000 on OpenAlexaffabout
Karen Chang, Dennis Gurwitz, Peter Azzopardi, Shaheen Doctor, Ronik Kanani, Constantine Petrou, Paul Meinert, Meera Umamaheswaran Kissoon

Bibliographic record

VenuePaediatrics & Child Health · 2016
Typearticle
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsNorth York General HospitalToronto East General HospitalThe Scarborough HospitalMcMaster UniversityUniversity of Toronto
Fundersnot available
KeywordsComputer scienceMedicine

Abstract

fetched live from OpenAlex

Re: Robinson JL, Le Saux N. Preventing Hospitalizations for Respiratory Syncytial Virus (RSV) Infection. Canadian Paediatric Society Infectious Diseases and Immunization Committee. Paediatr Child Health 2015;20(6):321–33. To the Editor; We are a group of paediatricians who wish to express major concerns about this particular Position Statement, published in the August/September 2015 issue of the Journal, and its implications for children and families within our community. Several of the quotes are incorrect, which reflects an incomplete search of the relevant scientific literature. In the United States outcomes registry (2000–2001), 75% of all RSV-related hospitalizations (RSVH) occurred between the first and second injection intervals (1), and the highest RSVH percentage (31%) was also noted in the same time interval in 2000–2004 (2). Palivizumab does prevent intensive care unit admissions, and the Cochrane meta-analysis (n=2789) confirms the same (RR 0.50 [95% CI 0.30 to 0.81]) (3). In a randomized trial, palivizumab recipients also had a statistically lower incidence of medically attended, non-hospitalized RSV infection, suggesting an attenuated effect on disease severity (4). The recommendation for three to five doses is based on low-quality evidence through observational studies without palivizumab levels (5,6). Reports confirm that after three doses, 52% and 85% of infants have palivizumab levels <5th percentile, respectively (7,8). Moreover, the quoted article recommending four doses “emphasizes the importance of testing the regimen in randomized trials before adoption” (9). The key message from the systematic review of observational studies was similarly overlooked (10). The review supports palivizumab for preterms < 33 weeks' gestational age (GA), children with chronic lung (CLD) and hemodynamically significant congenital heart disease (HSCHD) (10). Finally, healthy preterms are at greater risk for RSVH than term infants and the magnitude of difference is two-to threefold higher up to two years of age (11).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.060
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: Editorial
Teacher disagreement score0.924
Threshold uncertainty score0.254

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.060
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0020.001
Science and technology studies0.0020.002
Scholarly communication0.0060.005
Open science0.0040.002
Research integrity0.0150.014
Insufficient payload (model declined to judge)0.0760.053

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.349
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes2
Has abstractyes

Explore more

Same venuePaediatrics & Child Health→Same topicRespiratory viral infections research→French-language works237,207→